Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment

Oncogene

Volumn 35, Issue 11, 2016, Pages 1445-1456

  Deguchi, A ^a   Tomita, T ^a   Ohto, U ^b   Takemura, K ^b   Kitao, A ^b   Akashi Takamura, S ^c   Miyake, K ^b   Maru, Y ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; ERITORAN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN MD 2; TOLL LIKE RECEPTOR 4; CALGRANULIN B; CCL2 PROTEIN, MOUSE; DISACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LY96 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYD88 PROTEIN, MOUSE; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN BINDING; S100A8 PROTEIN, MOUSE; S100A9 PROTEIN, MOUSE; SUGAR PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; LEWIS CARCINOMA; LEWIS LUNG CARCINOMA CELL; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BINDING; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BIOSYNTHESIS; C57BL MOUSE; CARCINOMA, LEWIS LUNG; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BINDING SITES; CALGRANULIN A; CALGRANULIN B; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; DISACCHARIDES; ENZYME ACTIVATION; HUMANS; INTERLEUKIN-6; LYMPHOCYTE ANTIGEN 96; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; OXIDATION-REDUCTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; SUGAR PHOSPHATES; TOLL-LIKE RECEPTOR 4; TUMOR MICROENVIRONMENT;

EID: 84945310707     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.211     Document Type: Article

References (73)

1. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999; 1450: 191-231.
2. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21: 134-140.
3. Hunter MJ, Chazin WJ. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J Biol Chem 1998; 273: 12427-12435.
4. Vogl T, Leukert N, Barczyk K, Strupat K, Roth J. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochim Biophys Acta 2006; 1763: 1298-1306.
5. Grimbaldeston MA, Geczy CL, Tedla N, Finlay-Jones JJ, Hart PH. S100A8 induction in keratinocytes by ultraviolet A irradiation is dependent on reactive oxygen intermediates. J Invest Dermatol 2003; 121: 1168-1174.
6. Kumar RK, Yang Z, Bilson S, Thliveris S, Cooke BE, Geczy CL. Dimeric S100A8 in human neutrophils is diminished after phagocytosis. J Leukoc Biol 2001; 70: 59-64.
7. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003; 170: 3233-3242.
8. Hessian PA, Edgeworth J, Hogg N. MRP-8 and MRP-14, two abundant Ca(2 +)-binding proteins of neutrophils and monocytes. J Leukoc Biol 1993; 53: 197-204.
9. Kumar A, Steinkasserer A, Berchtold S. Interleukin-10 influences the expression of MRP8 and MRP14 in human dendritic cells. Int Arch Allergy Immunol 2003; 132: 40-47.
10. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006; 113: 2278-2284.
11. Zreiqat H, Howlett CR, Gronthos S, Hume D, Geczy CL. S100A8/S100A9 and their association with cartilage and bone. J Mol Histol 2007; 38: 381-391.
12. Passey RJ, Williams E, Lichanska AM, Wells C, Hu S, Geczy CL et al. A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol 1999; 163: 2209-2216.
13. Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, Yen T et al. Regulation of S100A8 by glucocorticoids. J Immunol 2005; 174: 2318-2326.
14. Xu K, Yen T, Geczy CL. Il-10 up-regulates macrophage expression of the S100 protein S100A8. J Immunol 2001; 166: 6358-6366.
15. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem 2005; 280: 41521-41529.
16. Yen T, Harrison CA, Devery JM, Leong S, Iismaa SE, Yoshimura T et al. Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood 1997; 90: 4812-4821.
17. Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K. S100 proteins in the epidermis. J Invest Dermatol 2004; 123: 23-33.
18. Rahimi F, Hsu K, Endoh Y, FGF-2 Geczy CL. IL-1beta and TGF-beta regulate fibroblast expression of S100A8. FEBS J 2005; 272: 2811-2827.
19. Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S et al. Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci USA 2010; 107: 13063-13068.
20. Kerkhoff C, Nacken W, Benedyk M, Dagher MC, Sopalla C, Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J 2005; 19: 467-469.
21. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004; 104: 4260-4268.
22. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272: 9496-9502.
23. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86: 557-566.
24. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276: 31332-31339.
25. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002; 277: 15028-15034.
26. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-11947.
27. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049.
28. Deguchi A, Tomita T, Omori T, Komatsu A, Ohto U, Takahashi S et al. Serum amyloid A3 binds MD-2 to activate p38 and NF-kappaB pathways in a MyD88-dependent manner. J Immunol 2013; 191: 1856-1864.
29. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008; 10: 1349-1355.
30. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; 18: 1279-1285.
31. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-1029.
32. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887-2894.
33. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 10229-10233.
34. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-1179.
35. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168: 5233-5239.
36. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115: 2223-2233.
37. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhao JG et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 2011; 4: 75.
38. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-384.
39. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-1195.
40. Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006; 72: 1102-1113.
41. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 2003; 198: 1043-1055.
42. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007; 130: 906-917.
43. Tomita T, Sakurai Y, Ishibashi S, Maru Y. Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis. Oncogene 2011; 30: 3429-3439.
44. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-1375.
45. Propper C, Huang X, Roth J, Sorg C, Nacken W. Analysis of the MRP8-MRP14 protein-protein interaction by the two-hybrid system suggests a prominent role of the C-terminal domain of S100 proteins in dimer formation. J Biol Chem 1999; 274: 183-188.
46. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009; 7: e97.
47. Riva M, Kallberg E, Bjork P, Hancz D, Vogl T, Roth J et al. Induction of nuclear factor-kappaB responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology 2012; 137: 172-182.
48. Omori S, Kitao A. CyClus: a fast, comprehensive cylindrical interface approximation clustering/reranking method for rigid-body protein-protein docking decoys. Proteins 2013; 81: 1005-1016.
49. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007; 7: 1271-1285.
50. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003; 15: 5-11.
51. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150: 165-178.
52. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
53. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011; 9: 133-148.
54. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S et al. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 2011; 71: 1989-1998.
55. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 2012; 109: 17561-17566.
56. Mantovani A, Allavena P. The interaction of anticancer therapies with tumorassociated macrophages. J Exp Med 2015; 212: 435-445.
57. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
58. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 2001; 7: 232-236.
59. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008; 83: 1484-1492.
60. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-2043.
61. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009; 28: 4353-4363.
62. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69: 3105-3113.
63. Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D et al. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res 2014; 74: 5421-5434.
64. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007; 67: 10519-10527.
65. Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 2011; 34: 590-601.
66. Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumorbearing mice. Nat Med 2014; 20: 676-681.
67. Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 2013; 12: 1676-1687.
68. Hiratsuka S, Ishibashi S, Tomita T, Watanabe A, Akashi-Takamura S, Murakami M et al. Primary tumours modulate innate immune signalling to create premetastatic vascular hyperpermeability foci. Nat Commun 2013; 4: 1853.
69. Ewens A, Mihich E, Ehrke MJ. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res 2005; 25: 3905-3915.
70. Ohto U, Fukase K, Miyake K, Shimizu T. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Natl Acad Sci USA 2012; 109: 7421-7426.
71. Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins 2003; 52: 80-87.
72. Pierce BG, Hourai Y, Weng Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One 2011; 6: e24657.
73. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3: 667-672.